Phase 2 Leukaemia Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with a specific type of blood cancer called APL (Acute Promyelocytic Leukaemia), confirmed by specific genetic tests showing a particular gene change called PML-RAR-alpha
- People who are able to understand the study and are willing to sign a written consent form showing they understand this is a research study
- People who have already started urgent APL treatment (such as ATRA, ATO, and/or one dose of idarubicin) before enrolling, as emergency treatment may have been needed right away
- Women who could become pregnant must have a negative pregnancy test at the start of the study, and another negative pregnancy test within 48 hours before taking the study drug
- All participants who are sexually active and could father or become pregnant must agree to use 2 effective forms of contraception throughout the entire study
Who may not be able to join:
- People whose heart electrical activity test (ECG) shows a specific measurement called QTcF that is longer than 480 milliseconds, indicating a possible heart rhythm concern
- People with kidney function test results more than 2.5 times above the normal range, unless the treating doctor determines this is caused by the leukaemia itself, a condition called haemolysis, or Gilbert's disease
- People with liver test results (total bilirubin) at 2 times or more above the normal range, unless the treating doctor determines this is caused by the leukaemia itself, haemolysis, or Gilbert's disease
- People with elevated liver enzyme levels (ALT/AST) more than 3 times above the normal range, unless the treating doctor determines this is caused by the leukaemia itself, haemolysis, or Gilbert's disease
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Farhad Ravandi-Kashani, M.D. Anderson Cancer Center
Phone: 713-745-0394
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Event free survival
Can't join this trial?
Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.